Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Cerebrolysin and Pinealon — mechanism, side effects, legal status, and pricing.
Cerebrolysin is not a single peptide but a complex biologic produced by enzymatic hydrolysis of purified porcine brain tissue, containing low-molecular-weight peptides (<10 kDa) and free amino acids. Manufactured by EVER Pharma (Austria), it is registered in 50+ countries (Europe, Asia, Russia, Latin America) for ischemic stroke, traumatic brain injury, and dementia, but is NOT FDA-approved in the United States.
Cerebrolysin
Pinealon
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Cerebrolysin
3 vendors list this, but none clear the trust bar (score ≥70) yet.
Check Cerebrolysin prices →Pinealon
COA corpus from Disclosed Labs — independently tested batches only.
Cerebrolysin
1
COAs
—
Avg purity
1
Labs
Pinealon
30
COAs
98.7%
Avg purity
9
Labs
The CASTA trial (Heiss et al., Stroke 2012, PMID 22282884, n=1070) failed its primary endpoint in Asian ischemic stroke patients, though a post-hoc subgroup with NIHSS >12 showed favorable mortality and functional trends. The CARS trial (Muresanu et al., Stroke 2016, PMID 26564102) reported improved upper-extremity motor recovery at day 90 with 30 mL/d for 21 days alongside rehabilitation. The Guekht 2011 vascular-dementia RCT (PMID 20656516, n=242) reported ADAS-cog+ and CIBIC+ improvements vs placebo. A 2023 Cochrane review (Ziganshina et al., PMID 37818733) concluded moderate-certainty evidence that Cerebrolysin/Cerebrolysin-like peptide mixtures probably do not reduce all-cause death in acute ischemic stroke, and flagged a possible increase in non-fatal serious adverse events. Many pivotal trials are industry-sponsored, and batch-to-batch variability as a porcine-brain hydrolysate is an ongoing methodological concern.
Key references
Khavinson et al. (Rejuvenation Research, 2011, PMID 21978084) reported that Pinealon suppressed reactive oxygen species accumulation, reduced cell death, and modulated cell-cycle progression across multiple cell types under oxidative stress, with the authors suggesting direct genome-level interaction. Arutjunyan et al. (International Journal of Clinical and Experimental Medicine, 2012, PMID 22567179) reported that Pinealon administered to pregnant rats on a methionine (hyperhomocysteinemia) diet improved spatial learning and reduced ROS accumulation in cerebellar neurons of offspring. The evidence base is dominated by Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and has not been independently replicated in Western clinical trials. No Phase II or III trials exist; Pinealon is not FDA-approved.
Cerebrolysin and Pinealon are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs